Literature DB >> 6976690

Serum sickness following streptokinase therapy.

W G Totty, T Romano, G M Benian, L A Gilula, L A Sherman.   

Abstract

Mesh:

Substances:

Year:  1982        PMID: 6976690     DOI: 10.2214/ajr.138.1.143

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


× No keyword cloud information.
  9 in total

1.  Serum sickness and acute renal failure after streptokinase therapy for myocardial infarction.

Authors:  K A Davies; P Mathieson; C G Winearls; A J Rees; M J Walport
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

2.  Crescentic glomerulonephritis: a possible complication of streptokinase treatment for myocardial infarction.

Authors:  N Murray; J Lyons; M Chappell
Journal:  Br Heart J       Date:  1986-11

3.  Technique and results of "higher-dose" infusion.

Authors:  T McNamara
Journal:  Cardiovasc Intervent Radiol       Date:  1988       Impact factor: 2.740

4.  Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

Authors:  C Bucknall; C Darley; J Flax; R Vincent; D Chamberlain
Journal:  Br Heart J       Date:  1988-01

5.  Rash after treatment with anistreplase.

Authors:  N Burrows; R R Jones
Journal:  Br Heart J       Date:  1990-10

6.  Acute renal failure following intravenous streptokinase infusion for acute myocardial infarction.

Authors:  Y Birnbaum; B Strasberg; E Rechavia; Y Neuman; B Stahl
Journal:  West J Med       Date:  1993-04

7.  Immunology of streptokinase in human subjects.

Authors:  K McGrath; R Patterson
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

8.  Indications for thrombolytic therapy in acute pulmonary embolism.

Authors:  J A Dieck; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1989

9.  Henoch-Schoenlein purpura due to streptokinase.

Authors:  A P Zilliox; D T Domoto; P S Hutcheson; C C Tsai; R G Slavin
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.